Notably, tumor growth rate upon treatment with RGS alone was comparable to that of ICB, suggesting that treatment alone may be effective in slowing tumor growth for melanoma patients with primary or secondary resistance to ICB treatment. The gene discussed is PITX2; the disease is neoplasm.